Graduate Institute of Microbiology and Immunology, National Yang-Ming University,1 Institute of Molecular Biology, Academia Sinica,2 Graduate Institute of Immunology, National Taiwan University, Taipei, Taiwan, Republic of China3
Received 20 July 2004/ Returned for modification 9 September 2004/ Accepted 16 November 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The ubiquitin-proteasome system controls intracellular protein degradation (13, 37). Ubiquitination starts from ATP-dependent and ubiquitin-activating enzyme (E1)-mediated ubiquitin conjugation to E1, followed by ubiquitin-conjugation enzyme (E2)-catalyzed transesterification of the E1-attached ubiquitin to E2. Ubiquitin-protein isopeptide ligase (E3), binding specifically to both E2 and the target protein, then promotes the transfer of ubiquitin to the target protein. From their structures, E3 enzymes have been classified into two distinct types: those possessing a HECT domain and those with a RING finger (18, 20). RING fingers are zinc-binding motifs with eight conserved cysteine and histidine residues. As RING finger proteins, Deltex family members were recently found to possess ubiquitin-protein isopeptide ligase (E3) activity (41). Through its own E3 activity, Deltex promotes self-ubiquitination (41); however, the in vivo substrate of DTX E3 ligase remains unknown.
Mitogen-activated protein kinase (MAPK) cascades mediate signal transduction from external stimulus to the nuclei (25, 36). MAP kinase kinase kinase 1 (MEKK1) is a 195-kDa protein with a C-terminal protein kinase domain and a large noncatalytic N terminus (26, 48). MEKK1 is processed by caspase-3-like protease to generate the 91-kDa C terminus kinase domain [MEKK1(C)] (43). Although MEKK1 is a primary activator for JNK through phosphorylation of stress-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (SEK, MKK4) (33, 43, 48, 51), MEKK1 can also regulate the ERK pathway (22, 49). Target gene disruption of MEKK1 has been shown to eliminate stress-induced JNK activation and reduce hyperosmolarity- and serum-stimulated ERK activation (47, 52). MEKK1 binds to a number of signaling proteins such as JNK, ERK2, MKK4, Raf-1, RhoA, TRAF2, and germinal center kinase (2, 3, 10, 22, 47, 49). Among these interactions, the simultaneous binding of MEKK1 to TRAF2 and germinal center kinase results in the activation of MEKK1 (2, 3). However, the in vivo significance of most MEKK1-dependent interactions remains unclear (10).
In the present study, we observed that Deltex is a physiological regulator of T-cell activation. Deltex inhibited T-cell activation not at the stage of T-cell receptor engagement but at the levels of MAPK activation. One of the defects identified in Deltex-overexpressing T cells was the diminished levels of MEKK1(C). We further demonstrated that Deltex is a ubiquitin E3 ligase for MEKK1(C). Our results reveal a novel function of Deltex through selective degradation of MEKK1.
| MATERIALS AND METHODS |
|---|
|
|
|---|
(C-20), c-Fos (H-125), MEKK1 (C-22), MEKK2 (N-19), HPK1 (N-19), MKK1 (H-8), MKK3 (I-20), MKK4 (C-20), MKK6 (K-19), MKK7 (C-19), Ub (FL-76), Myc (9E10), His (H-3). Anti-Raf-1 (c-Raf-1, clone 52) was obtained from Transduction Lab. Anti-phospho-ERK (T202/Y204), anti-phospho (T180/Y182)-p38 MAPK, anti-phosphor-LAT (Y191), anti-I
B
, and anti-phospho-PKC
(T538) were purchased from Cell Signaling (Beverly, Mass.). Goat anti-glutathione S-transferase (GST) was acquired from Amersham (Buckinghamshire, United Kingdom). Anti-ß-tubulin was obtained from Upstate (Lake Placid, N.Y.). Rabbit polyclonal serum against GST-Deltex1 was obtained from IgMedica Biotech (Taipei, Taiwan). Interleukin-2 (IL-2)-chloramphenicol acetyltransferase (CAT) (34) was a gift from Ellen Rothenberg (California Institute of Technology, Pasadena), and CAT assays were conducted as previously described (14). Full-length MEKK1 cDNA (48) was a gift from Melanie H. Cobb (University of Texas, Dallas). MEKK1 active-form MEKK (3')-5'EE-CMV [abbreviated as MEKK1(C) here] (51) was a gift from Dennis Templeton (Case Western Reserve University, Cleveland, Ohio). PCR primers for detecting Deltex1 are as follows: 5' GTA AGG CTT CAA GGG GTC GCT and 3' CTC AGC TTG ATG CGT GTA TAG CC. PCR primers for detecting MEKK1 are as follows: 5' TGG CTG TGA AAC AGG TGA and 3' AAG TTC TAA GCA GCG CAC. Retroviral infection of T cells. Mouse Deltex1 cDNA (24) was a gift from Hideyuki Okano (Keiko University, Tokyo, Japan). pGCIRES-YFP, a homologue of pGCIRES-GFP (5), was a gift from Gina Costa (Stanford University, Stanford, Calif.) and was obtained through Nan-Shih Liao (Academia Sinica, Taipei, Taiwan). Myc-tagged Deltex1 was cloned into pGC-IRES-YFP. Retroviruses were produced by transfecting Phoenix-Eco cells (gifts of Garry P. Nolan, Stanford University) with 10 µg of pGC-IRES-YFP or pGC-DTX1-IRES-YFP plasmids. Phoenix cell supernatants containing retrovirus were collected 48 h and 72 h after transfection. Viral titers were determined using NIH 3T3 cells, and virus stocks with titers greater than 1 x 106 were used for spin infection of DO11.10 T and splenic T cells (9). Splenic T cells were isolated by extensive panning against anti-mouse immunoglobulin and then activated by plate-bound anti-CD3 plus anti-CD28 in the presence of IL-2 (2 U/ml) for 2 days. The infection efficiency was 60% for DO11.10 and 20% for activated splenic T cells. Forty-eight hours after infection, yellow fluorescent protein (YFP)-expressing DO11.10 cells and splenic T cells were isolated by sorting on a FACSVantage SE sytstem (Becton Dickinson, Mountain View, Calif.).
Protein kinase assay. Cell lysates were prepared 24 h after transfection, and 100 to 200 µg of lysate was precipitated with 1 µl of anti-JNK1 Ab101 (32) (gift of Tse-Hua Tan, Baylor Medical School) followed by 20 µl of protein A-Sepharose. The kinase activity of the immune complexes was determined by using GST-c-Jun (1-79) as substrates (4). The reaction mixtures were resolved on SDS-PAGE, followed by autoradiography, and quantitated by PhosphorImager (Molecular Dynamics).
siRNA. Murine deltex1 small interfering RNA (siRNA) sequence (D-010470-02; Dharmacon, Lafayette, Colo.) was subcloned into pSuper.gfp/neo (DNAengine, Seattle, Wash.), in which enhanced green fluorescent protein (EGFP) expression was driven by Phosphoglycerate kinase promoter. T cells were transfected with pSuper or pSuper-DTXsiRNA by electroporation. The EGFP-expressing fraction was sorted on a FACSVantage SE 48 h after transfection. A fraction of cells were collected for cell lysate preparation and RNA isolation, and the rest of the cells were stimulated with plate-bound CD3/CD28 antibodies and IL-2 quantitated 16 h after activation. For murine MEKK1, a pool of four specific siRNA duplexes (M-010471-00) were synthesized by Dharmacon. siRNA (500 nM) (containing four duplexes) was mixed with 2 x 106 T cells (DO11.10 or EL4) in 100 µl of Cell Line Nucleofector Solution V (Amaxa, Koeln, Germany), and electroporation was conducted on a Nucleofector. Forty-eight hours after transfection, the levels of MEKK1 and IL-2 production were similarly determined. The densitometry measurements were performed on a LAS-1000 luminescent image analyzer (Fuji Photo Film Co., Tokyo, Japan) with Image Gauge software (version 3.2; Fuji). Quant mode was used to select the reading area and to subtract background. The reading of the sample from the control T cells (mock transfected or pSuper vector transfected) was then set as 1 to get the preliminary n-fold of change for the siRNA-transfected T-cell samples. The final n-fold of change was obtained after normalization with ß-tubulin contents.
GST pull-down assay. His6-MEKK1(C) and His6-MEKK1(FL) were produced by subcloning MEKK1(C) (874 to 1493 amino acids) and MEKK1(FL) (1 to 1493 amino acids), respectively, into pRSET-a (Invitrogen) for N-terminal His6 flanking. Recombinant His6-MEKK1(C) and His6-MEKK1(FL) were then purified on Ni-nitrilotriacetic acid (NTA) agarose (QIAGEN). Cell lysates for the GST pull-down assay were prepared in GSH binding buffer (50 mM potassium phosphate buffer, pH 7.5, 150 mM KCl, 1 mM MgCl2, 10% glycerol, 1% Triton X-100, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride). Five micrograms of GST-fusion protein (GST-Deltex) was loaded onto GSH agarose (20 µl, 50% slurry) and incubated with 100 to 200 µg of cell lysates overnight at 4°C or with 5 µg of His6-MEKK1(C) or His6-MEKK1(FL) for 2 h at 4°C. GST agarose beads were then washed three times with binding buffer and analyzed on SDS-PAGE.
In vitro ubiquitination assay. The in vitro ubiquitination reaction mixture contained bovine ubiquitin (1 µg), rabbit E1 (0.2 µg), UbcH5c (0.2 µg), GST-Deltex (0.2 µg), and His6-MEKK1(C) (0.5 µg) in 20 µl of reaction buffer (25 mM Tris, pH 7.5, 50 mM NaCl, 10 mM MgCl2, 2 mM ATP, 0.5 mM dithiothreitol). The reaction proceeded at 30°C for 30 min. Eighty microliters of reaction buffer and 20 µl of 50% slurry Ni-NTA agarose were then added and mixed at 4°C for 2 h to pull down His6-MEKK1(C). Ni-NTA agarose was then washed three times with ice-cold reaction buffer, resuspended in SDS sample buffer, and resolved on SDS-PAGE. The amount of ubiquitin associated was determined by blotting with ubiquitin antibody.
| RESULTS |
|---|
|
|
|---|
|
|
.
Since the expression of IL-2 in naive T cells is determined primarily by transcription activation of the IL-2 gene promoter (19), we next determined whether activation of the major transcription elements, NF-
B, NFAT, and AP-1 on the IL-2 gene promoter were affected by Deltex1 cotransfection. Deltex did not affect the activation of NF-
B (Fig. 3A), while it partially inhibited the induction of NFATc (Fig. 3B) and c-Fos (Fig. 3C) and effectively prevented c-Jun phosphorylation (Fig. 3D). Consistent with results on the nuclear appearance of the specific transcription factor, overexpression of Deltex in T cells repressed the activation of IL-2-CAT and AP-1-CAT (data not shown). JNK, ERK, and p38 MAPK contribute to c-Fos induction, c-Jun activation, and NFATc expression (23, 25, 46). We then determined the effect of Deltex on activation of JNK, ERK, and p38 MAPK. Consistent with a reduction in c-Jun Ser63 phosphorylation, CD3/CD28-triggered JNK activation, measured by phosphorylation of GST c-Jun (1-79), was largely attenuated in EL4 and DO11.10 T cells expressing Deltex1 (Fig. 4A; data not shown for DO11.10). A moderate decrease in ERK activation, assessed by phosphorylation of ERK, was also found in DO11.10 and EL4 T cells expressing Deltex1 compared with the YFP control (Fig. 4B; data not shown for EL4). An effective inhibition of p38 MAPK was observed in Deltex-expressing T cells (Fig. 4C). We thus studied whether defective MAPK activation could be attributed to an inhibition on proximal TCR activation by Deltex. TCR engagement is immediately followed by recruitment and tyrosine phosphorylation of the adaptor protein LAT; LAT is pivotal for activation of AP-1 and ERK (40). Figure 4D illustrates that anti-CD3 stimulation of T cells led to extensive LAT phosphorylation, identical in Deltex1-DO11.10 and YFP-DO11.10 cells, suggesting that Deltex1 does not affect early T-cell activation at the stage of LAT phosphorylation. We also determined the activation of PKC
, another key signaling molecule in early T-cell activation (16). PKC
has been shown to stimulate Ras-dependent transcription activation of AP-1 in T cells and to cooperate with calcineurin for JNK activation and IL-2 gene expression (1, 42). The level of PKC
phosphorylation after TCR ligation was also similar for the Deltex-expressing T cells and the YFP control (Fig. 4D). Therefore, the stages of TCR activation that are regulated by Deltex1 should be downstream of the LAT and PKC
activation.
|
|
|
|
Ubiquitin-mediated MEKK1(C) degradation in Deltex-expressing T cells. To examine whether the Deltex-directed MEKK1(C) reduction was due to proteasome-dependent degradation, T cells were treated with the proteasome inhibitor MG132. MG132 treatment had no effect on the level of MEKK1(FL) and MEKK1(C) in YFP control T cells (Fig. 7A). In contrast, MG132 restored MEKK1(C) expression in Deltex1-expressing T cells, indicating that Deltex1 triggered MEKK1(C) degradation in a proteasome-dependent manner (Fig. 7A). We next determined whether Deltex1 promoted the ubiquitination of MEKK1(C). MEKK1 was precipitated from T cell lysate and immunoblotted with antiubiquitin. MEKK1 was not ubiquitinated in control YFP T cells (Fig. 7B). However, ubiquitin modification of MEKK1(C), characterized by the presence of multiple MEKK1 protein bands, was evident in T cells expressing Deltex1. The level of MEKK1(C) ubiquitination was prominent when protein degradation was blocked by addition of MG132 to Deltex1-DO11.10 T cells (Fig. 7B). Similar results were found in splenic T cells, where Deltex1 expression resulted in extensive MEKK1 ubiquitination (Fig. 7C). Since MEKK1(C) is the only form of MEKK1 in splenic T cells (Fig. 5D), the high-molecular-weight ubiquitin conjugates (Fig. 7C) apparently came from MEKK1(C). These results suggest that Deltex1 targets MEKK1(C) for ubiquitin conjugation and concomitant proteasome-mediated degradation in T cells.
|
|
RF-Myc). Deletion of RING finger domain did not affect the binding of Deltex to MEKK1(C) (Fig. 8C) but abolished the capacity of Deltex1 to trigger MEKK1(C) ubiquitination (Fig. 9A). These results demonstrated that DTX acts as an E3 ligase for the ubiquitination of the C-terminal of MEKK1 in vivo.
|
RF) was added to the same reaction, suggesting that the RING finger domain is required for Deltex to induce MEKK1(C) ubiquitination. | DISCUSSION |
|---|
|
|
|---|
We also used Deltex-specific siRNA to demonstrate the physiological role of Deltex in regulating T-cell activation (Fig. 1E to G). Even if Deltex1 levels were attenuated by TCR stimulation (Fig. 1A to D), a reduced Deltex1 expression prior to T-cell activation further enhanced TCR-stimulated IL-2 production, suggesting a pivotal role of Deltex in T-cell activation events. Several signaling pathways affected by Deltex, including activation of AP-1 and NFATc and stimulation of JNK, p38 MAPK, and ERK, were identified by Deltex1 overexpression (Fig. 3 and 4). Most of these activation defects are known to be involved in T-cell activation. For example, previous studies have established a critical role of p38 MAPK in T-cell activation (15, 29, 39, 46), that interference of p38 MAPK activation severely impairs T-cell activation. For NFAT and AP-1, their coordinated association on the IL-2 gene promoter dictates the expression of the IL-2 gene (19). Interestingly, with the profound inhibition of quite a few downstream signals, the proximal TCR activation events were mostly unaffected by Deltex1. The activation of LAT and PKC
was normal in the presence of Deltex overexpression (Fig. 4D). Instead, one of the defects was mapped to selective degradation of MEKK1 (Fig. 5B). This was best illustrated by the exact inverse correlation between the expression of Deltex1 and the levels of MEKK1 in T cells. In the absence of any Deltex1 overexpression, TCR stimulation down-regulated Deltex1, with a simultaneous up-regulation of MEKK1 (Fig. 1A to D and Fig. 6A). In addition, reduced Deltex1 expression by siRNA in T cells (Fig. 1E) led to a significant increase of MEKK1(C) protein (Fig. 5E).
Interference of JNK activation by Deltex has been previously suggested, based on the suppression of Ras-dependent c-Jun activation by Deltex (35). The present study provides the first direct proof that JNK activation is profoundly attenuated by Deltex (Fig. 4A). We also found that ERK activation was partially inhibited by Deltex1 (Fig. 4B). It has been shown that MEKK1 gene knockout results in severe reduction in JNK activity and mild inhibition of ERK activity (52), a phenotype similar to our Deltex1-expressing T cells. Despite the fact that the link between MEKK1 and p38 MAPK is less direct (52), p38 MAPK has been shown to be activated by MEKK1 in many different cells (6, 8, 11, 44, 46). Therefore, defects in the activation of JNK, p38 MAPK, and ERK in Deltex1-expressing T cells could be attributed, at least in part, to the down-regulation of MEKK1(C). It has to be noted that we do not exclude the possibility that Deltex expression leads to defects in additional signal molecules and contributes to the aberrant MAPK activation observed here.
Our results further demonstrated, likely for the first time, that MEKK1 is essential for TCR signal transduction. There are more than 12 different MAP kinase kinases in mammalian cells (25, 36), suggesting a possible signaling redundancy among several MAP kinase kinases, which makes defining the specific involvement of a MAP kinase kinase downstream of the T-cell receptor difficult. Activation of MEKK1 by TCR ligation has been previously demonstrated (1, 21). Whether MEKK1 is essential for T-cell activation, however, remains unclear. Our observations that down-regulation of MEKK1 by Deltex resulted in inactivation of JNK and p38 MAPK and a decrease in IL-2 generation (Fig. 2, 4, and 5), together with the finding that T-cell activation was suppressed when MEKK1 was specifically reduced by siRNA (Fig. 6), clearly support an indispensable role of MEKK1 in T-cell activation.
A critical observation from the present study is the identification of MEKK1 as a substrate of Deltex E3 ligase. The C terminus of Deltex is a RING finger, a domain present in many E3 ligases and functioning to bind E2 (18, 20). Deltex1 has since been shown to exhibit E3 ligase activity based on its ability to promote self-ubiquitination (41), despite the fact that the in vivo targets of Deltex1 E3 activity remain unknown. Our results illustrate the in vivo E3 ligase activity of Deltex1 and identify MEKK1(C) as the first known physiological target of Deltex E3 ligase. Deltex interacted directly with MEKK1(C), as shown by coimmunoprecipitation and GST pull-down analysis (Fig. 8). Deltex1 bound substrate MEKK1(C) through a region distinct from its RING finger (Fig. 8C), consistent with the function of the RING finger for E2 association. Deltex1 promoted MEKK1(C) ubiquitination when coexpressed with MEKK1(C) in cells (Fig. 9A) or coincubated with recombinant MEKK1(C) in the presence of E1 and E2 (Fig. 9B). Deletion of the RING finger, the E2-binding domain, abolished the ability of Deltex1 to stimulate MEKK1(C) ubiquitination (Fig. 9B) despite the fact that Deltex1 still interacted with MEKK(C) (Fig. 8C). Deltex1 fulfills all the criteria for an E3 ligase specific for MEKK1(C).
Another important finding here is that Deltex is a ubiquitin ligase for MEKK1(C) but much less so for MEKK1(FL). In contrast to the effective interaction between MEKK1(C) and Deltex1, the binding of MEKK1(FL) to Deltex was minimum (Fig. 8). The ability of a substrate to bind to a specific E3 is a prerequisite for ubiquitin transfer mediated by the given E3. The differential effect of Deltex1 on the degradation of MEKK1(C) and MEKK1(FL), therefore, could be attributed to the distinct binding affinity for Deltex1 between MEKK1(C) and MEKK1(FL). At present, the cause for the poor interaction between MEKK1(FL) and Deltex is not understood. In addition to the C-terminal kinase domain, the full-length MEKK1 contains a long N-terminal domain (48) with proline-rich domains for binding to SH3, sequences for binding to 14-3-3, and pleckstrin homology domains (25, 36). A possibility is that interaction of MEKK1(FL) with other signaling molecules in vivo prevents the binding of Deltex to MEKK1(FL). Alternatively, the long N-terminal region of MEKK1(FL) may shield the Deltex-binding area of MEKK1(C) from Deltex interaction. A study is ongoing to delineate these two possibilities.
It is interesting that recent findings show that the plant homeodomain of MEKK1 is an E3 ubiquitin ligase and mediates the degradation of ERK (27, 45). Together with results from the present study, there are two parallel ubiquitin conjugation pathways centered on MEKK1; MEKK1(C) is degraded through ubiquitination by Deltex E3, while MEKK1(FL) acts as an E3 for other signaling proteins. A potential physiological significance of the resistance of MEKK1(FL) to Deltex1-mediated ubiquitination could be an assurance of the operation of the MEKK1(FL) E3 pathway by preventing unnecessary degradation of MEKK1(FL).
Both full-length MEKK1 and MEKK1(C) activate JNK; the processing of full-length MEKK1 to MEKK1(C) is not essential for activation of JNK (43). Blockage of caspase-mediated MEKK1 cleavage by specific inhibitors does not interfere with the downstream JNK and ERK activation, and neither does mutation of the caspase-3 recognition sites (DEVE
A860 and DTVD
A874) on MEKK1 affect JNK activation (43). Therefore, MEKK1(FL) may convey sufficient JNK activation in the absence of MEKK1(C) generation. MEKK1(C), however, is the dominant form of MEKK1 in T cells (Fig. 5F). Deltex-mediated degradation of MEKK1(C) eliminates most of MEKK1 in T cells (Fig. 5B and D), leading to defective T-cell activation.
In summary, we identified a novel pathway regulating MEKK1 stability and T-lymphocyte activation by the Notch signal mediator Deltex. As an E3 ligase, Deltex1 binds specifically to its target MEKK1(C) and mediates the transfer of ubiquitin from the RING finger-associated E2 to MEKK1(C). MEKK1(C) is a key to T-cell activation (Fig. 6) and its degradation by proteasome results in defective T-cell activation. The ubiquitin E3 ligase activity of Deltex is clearly dissociated from the transcription activity reported for Deltex (50) and may contribute to physiological activities previously thought to be Deltex independent. We are currently working to identify other substrates targeted by Deltex E3 ligase, which will help unveil additional functional roles of Deltex.
| ACKNOWLEDGMENTS |
|---|
This work was supported by grant 92-2320-B001-006 from the National Science Council, Taiwan, grant NHRI-EX93-9217BI from the National Health Research Institute, Taiwan, and a grant from Academia Sinica.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Baud, V., Z. G. Liu, B. Bennett, N. Suzuki, Y. Xia, and M. Karin. 1999. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev. 13:1297-1308.
3. Chadee, D. N., T. Yuasa, and J. M. Kyiakis. 2002. Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2. Mol. Cell. Biol. 22:737-749.
4. Chen, Y., and M. Z. Lai. 2001. JNK-induced apoptosis is independent of Fas ligand in Jurkat T cells. J. Biol. Chem. 276:8350-8357.
5. Costa, G. L., J. M. Benson, C. M. Seroogy, P. Achacoso, C. J. Fathman, and G. P. Nolan. 2000. Targeting rare populations of murine antigen-specific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease. J. Immunol. 164:3581-3590.
6. Cuenda, A., and D. S. Dorow. 1998. Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1. Biochem. J. 333:11-15.
7. Deftos, M. L., Y. W. He, E. W. Ojala, and M. J. Bevan. 1998. Correlating notch signaling with thymocyte maturation. Immunity 9:777-786.[CrossRef][Medline]
8. Efimova, T., P. LaCelle, J. F. Welter, and R. L. Eckert. 1998. Regulation of human involucrin promoter activity by a protein kinase C, Ras, MEKK1, MEK3, p38/RK, AP1 signal transduction pathway. J. Biol. Chem. 273:24387-24395.
9. Fang, L. W., T. S. Tai, W. N. Yu, F. Liao, and M. Z. Lai. 2004. Phosphatidylinositide 3-kinase priming couples c-FLIP to T cell activation. J. Biol. Chem. 279:13-18.
10. Gallagher, E. D., S. Gutowski, P. C. Sternweis, and M. H. Cobb. 2004. RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity. J. Biol. Chem. 279:1872-1877.
11. Guan, Z., S. Y. Buckman, A. P. Pentland, D. J. Templeton, and A. R. Morrison. 1998. Induction of cyclooxygenase-2 by the activated MEKK1
SEK1/MKK4
p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 273:12901-12908.
12. Gupta-Rossi, N., S. Storck, P. J. Griebel, C. A. Reynaud, J. C. Weill, and A. Dahan. 2003. Specific over-expression of DTX and a new Kelch-like protein in human germinal center B cells. Mol. Immunol. 39:791-799.[CrossRef][Medline]
13. Hershko, A., A. Ciechanover, and A. Varshavsky. 2000. The ubiquitin system. Nat. Med. 6:1073-1081.[CrossRef][Medline]
14. Ho, H. Y., H. H. Lee, and M. Z. Lai. 1997. Overexpression of mitogen-activated protein kinase kinase kinase reverses cAMP inhibition of NF-
B in T cells. Eur. J. Immunol. 27:222-226.[Medline]
15. Hsu, S. C., M. Gavrilin, M. H. Tsai, J. Han, and M. Z. Lai. 1999. p38 mitogen activated protein kinase is involved in Fas ligand expression. J. Biol. Chem. 274:25769-25776.
16. Isakov, N., and A. Altman. 2002. Protein kinase C
in T cell activation. Annu. Rev. Immunol. 20:761-794.[CrossRef][Medline]
17. Izon, D. J., J. C. Aster, Y. He, A. Weng, F. G. Karnell, V. Patriub, L. Xu, S. Bakkour, C. Rodriguez, D. Allman, and W. S. Pear. 2002. DTX1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. Immunity 16:231-243.[CrossRef][Medline]
18. Jackson, P. K., A. G. Eldridge, E. Freed, L. Furstenthal, J. Y. Hsu, B. K. Kaiser, and J. D. Reimann. 2000. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol. 10:429-439.[CrossRef][Medline]
19. Jain, J., C. Loh, and A. Rao. 1995. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7:333-342.[CrossRef][Medline]
20. Joazeiro, C. A., and A. M. Weissman. 2000. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549-552.[CrossRef][Medline]
21. Kaga, S., S. Ragg, K. A. Rogers, and A. Ochi. 1998. Activation of p21-CDC42/Rac-activated kinases by CD28 signaling: p21-activated kinase (PAK) and MEK kinase 1 (MEKK1) may mediate the interplay between CD3 and CD28 signals. J. Immunol. 160:4182-4189.
22. Karandikar, M., S. Xu, and M. H. Cobb. 2000. MEKK1 binds raf-1 and the ERK2 cascade components. J. Biol. Chem. 275:40120-40127.
23. Karin, M., Z. Liu, and E. Zandi. 1997. AP-1 function and regulation. Curr. Opin. Cell Biol. 9:240-246.[CrossRef][Medline]
24. Kishi, N., Z. Tang, Y. Maeda, A. Hirai, R. Mo, M. Ito, S. Suzuki, K. Nakao, T. Kinoshita, T. Kadesch, C. Hui, S. Artavanis-Tsakonas, H. Okano, and K. Matsuno. 2001. Murine homologs of DTX define a novel gene family involved in vertebrate Notch signaling and neurogenesis. Int. J. Dev. Neurosci. 19:21-35.[Medline]
25. Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:807-869.
26. Lange-Carter, C. A., C. M. Pleiman, A. M. Gardner, K. J. Blumer, and G. L. Johnson. 1993. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 260:315-319.
27. Lu, Z., S. Xu, C. Joazeiro, M. H. Cobb, and T. Hunter. 2002. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 9:945-956.[CrossRef][Medline]
28. Maillard, I., S. H. Adler, and W. S. Pear. 2003. Notch and the immune system. Immunity 19:781-791.[CrossRef][Medline]
29. Matsuda, S., T. Moriguchi, S. Koyasu, and E. Nishida. 1998. T lymphocyte activation signal for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK-JNK signaling pathways sensitive to cyclosporin A. J. Biol. Chem. 273:12378-12382.
30. Matsuno, K., R. J. Diederich, M. J. Go, C. M. Blaumueller, and S. Artavanis-Tsakonas. 1995. DTX acts as a positive regulator of Notch signaling through interactions with the Notch ankyrin repeats. Development 121:2633-2644.[Abstract]
31. Matsuno, K., D. Eastman, T. Mitsiades, A. M. Quinn, M. L. Carcanciu, P. Ordentlich, T. Kadesch, and S. Artavanis-Tsakonas. 1998. Human DTX is a conserved regulator of Notch signalling. Nat. Genet. 19:74-78.[CrossRef][Medline]
32. Meyer, C. F., X. Wang, C. Chang, D. Templeton, and T. H. Tan. 1996. Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating
B enhancer activation. J. Biol. Chem. 271:8971-8976.
33. Minden, A., A. Lin, M. McMahon, C. Lange-Carter, B. Derijard, R. J. Davis, G. L. Johnson, and M. Karin. 1994. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723.
34. Novak, T. J., P. M. White, and E. V. Rothenberg. 1990. Regulatory anatomy of the murine interleukin-2 gene. Nucleic Acids Res. 18:4523-4533.
35. Ordentlich, P., A. Lin, C. P. Shen, C. Blaumueller, K. Matsuno, S. Artavanis-Tsaonas, and T. Kadesch. 1998. Notch inhibition of E47 supports the existence of a novel signaling pathway. Mol. Cell. Biol. 18:2230-2239.
36. Pearson, G., F. Robinson, T. B. Gibson, B. E. Xu, M. Karandikar, K. Berman, and M. H. Cobb. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22:153-183.
37. Pickart, C. M. 2004. Back to the future with ubiquitin. Cell 116:181-190.[CrossRef][Medline]
38. Saito, T., S. Chiba, M. Ichikawa, A. Kunisato, T. Asai, K. Shimizu, T. Tamaguchi, G. Yamamoto, S. Seo, K. Kumano, E. Nakagami-Yamaguchi, Y. Hamada, S. Aizawa, and H. Hirai. 2003. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 18:675-685.[CrossRef][Medline]
39. Salojin, K. V., J. Zhang, and T. L. Delovitch. 1999. TCR and CD28 are coupled via ZAP-70 to the activation of the Vav/Rac-1-/PAK-1/p38 MAPK signaling pathway. J. Immunol. 163:844-853.
40. Samelson, L. E. 2002. Signal transduction mediated by the T cell antigen receptor: the role of adaptor protein. Annu. Rev. Immunol. 20:371-394.[CrossRef][Medline]
41. Takeyama, K., R. C. Aguiar, L. Gu, C. He, G. J. Freeman, J. L. Kutok, J. C. Aster, and M. A. Shipp. 2003. The BAL-binding protein BBAP and related DTX family members exhibit ubiquitin-protein isopeptide ligase activity. J. Biol. Chem. 278:21930-21937.
42. Werlen, G., E. Jacinto, Y. Xia, and M. Karin. 1998. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J. 17:3101-3111.[CrossRef][Medline]
43. Widmann, C., P. Gerwins, N. L. Johnson, M. B. Jarpe, and G. L. Johnson. 1998. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol. Cell. Biol. 18:2416-2429.
44. Winzen, R., M. Kracht, B. Ritter, A. Wilhelm, C. Y. Chen, A. B. Shyu, M. Muller, M. Gaestel, K. Resch, and H. Holtmann. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18:4969-4980.[CrossRef][Medline]
45. Witowsky, J. A., and G. L. Johnson. 2003. Ubiquitination of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. J. Biol. Chem. 278:1403-1406.
46. Wu, C. C., S. C. Hsu, H. M. Shih, and M. Z. Lai. 2003. NFATc is a target of p38 mitogen activated protein kinase in T cells. Mol. Cell. Biol. 23:6442-6454.
47. Xia, Y., Z. Wu, B. Su, B. Murray, and M. Karin. 1998. JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev. 12:3369-3381.
48. Xu, S., D. J. Robbins, L. B. Christerson, J. M. English, C. A. Vanderbilt, and M. H. Cobb. 1996. Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain. Proc. Natl. Acad. Sci. USA 93:5291-5295.
49. Xu, S., and M. H. Cobb. 1997. MEKK1 binds directly to the c-Jun N-terminal kinases stress-activated protein kinases. J. Biol. Chem. 272:32056-32060.
50. Yamamoto, N., S. Yamamoto, F. Inagaki, M. Kawaichi, A. Fukamizu, N. Kishi, K. Matsuno, K. Nakamura, G. Weinmaster, H. Okano, and M. Nakafuku. 2001. Role of DTX-1 as a transcriptional regulator downstream of the Notch receptor. J. Biol. Chem. 276:45031-45040.
51. Yan, M., T. Dal, J. C. Deak, J. M. Kyriakis, L. I. Zon, J. R. Woodgett, and D. J. Templeton. 1994. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372:798-800.[Medline]
52. Yujiri, T., S. Sather, G. R. Fanger, and G. L. Johnson. 1998. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 282:1911-1914.
53. Yun, T. J., and M. J. Bevan. 2003. Notch-regulated ankyrin-repeat protein inhibits Notch1 signaling: multiple Notch1 signaling pathways involved in T cell development. J. Immunol. 170:5834-5841.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||